The Medical Innovation Podcast
In this episode, we speak with Tina Liedtky, Global President of Transplant Diagnostics at Thermo Fisher Scientific, about how cutting-edge diagnostics and emerging AI are reshaping organ transplantation. Tina explains how HLA compatibility testing underpins successful transplant outcomes and how innovations like the non-invasive CXCL10 urinary biomarker are expanding access to post-transplant monitoring for patients far from clinical centers. We also explore her vision for AI's role in improving donor-recipient matching for highly sensitized patients, personalizing immunosuppressive regimens, and the strategic importance of partnerships for early-stage companies navigating this specialized and highly regulated field.
37 episodes
Comments
0Be the first to comment
Sign up now and become a member of the The Medical Innovation Podcast community!